Details of Disease

General Information of Disease (ID: DIST4788)

Disease Name	Non-alcoholic steatohepatitis
Synonyms	nonalcoholic steatohepatitis; NASH - nonalcoholic steatohepatitis; non-alcoholic steatohepatitis; MASH
Disease Class	DB92: Non-alcoholic fatty liver disease
Definition	Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) is a type of fatty liver disease. It often develops due to a metabolic disorder, such as obesity or diabetes, resulting in a toxic buildup of fat in the liver. It is the most severe form of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as nonalcoholic fatty liver disease or NAFLD).
Disease Hierarchy	DISDG1NL: Non-alcoholic fatty liver disease DISXXX35: Hepatitis DIST4788: Non-alcoholic steatohepatitis
ICD Code	ICD-11 ICD-11: DB92.1 ICD-10 ICD-10: K75.8 ICD-9 ICD-9: 571.8 Expand ICD-11 'DB92.1 Expand ICD-10 'K75.8 Expand ICD-9 571.8
Disease Identifiers	MONDO ID MONDO_0007027 MESH ID D065626 UMLS CUI C3241937 MedGen ID 469032 SNOMED CT ID 442685003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 26 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
A278	DMKXO9V	IND submitted	Small molecule	[1]
GFT-505	DM7ZOAE	Phase 3	NA	[2]
GS-9674	DM936V7	Phase 3	Small molecular drug	[3]
Aldafermin	DM5ITEZ	Phase 2	Protein	[4]
ASP9831	DM2MSGF	Phase 2	Small molecular drug	[5]
CRV431	DMW04YQ	Phase 2	Small molecular drug	[6]
EDP-305	DMGJYZ8	Phase 2	Small molecular drug	[7]
Efinopegdutide	DMAN2V2	Phase 2	Peptide	[8]
EYP001	DM5PBLM	Phase 2	Small molecular drug	[9]
GR-MD-02	DM9QF65	Phase 2	Protein	[10]
GSK4532990	DMBUAC6	Phase 2	NA	[11]
HU6	DMQ4523	Phase 2	Small molecule	[12]
ION839	DMWZT3N	Phase 2	Ligand-conjugated antisense	[13]
IVA337	DMJV3AX	Phase 2	Small molecular drug	[14]
LMB763	DMQOXNL	Phase 2	Small molecular drug	[15]
MET409	DM89QXT	Phase 2	Small molecular drug	[16]
MK-3655	DMM5SVL	Phase 2	Monoclonal antibody	[17]
PF-06865571	DMZE3GK	Phase 2	Small molecule	[18]
AGN-242266	DMVHPOX	Phase 1	Small molecular drug	[19]
AMG 609	DMVCA06	Phase 1	Small interfering RNA	[20]
AZD7503	DM8XJD2	Phase 1	Small molecule	[21]
CB4211	DMP2FP3	Phase 1	NA	[22]
HPP971	DMZXG7Q	Phase 1	Small molecular drug	[23]
ION 224	DMD7LHM	Phase 1	Antisense oligonucleotide	[24]
JNJ-75220795	DM2LQ5Z	Phase 1	NA	[25]
SAR-548304	DMJAZF4	Phase 1	NA	[26]
------------------------------------------------------------------------------------


⏷ Show the Full List of 26 Drug(s)

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AC-3174	DMNUE4H	Investigative	Small molecular drug	[27]
AK-20	DME4JAQ	Investigative	NA	[28]
MitoAscorbate	DM8EU8B	Investigative	NA	[28]
MitoLinoleic	DMU8LRD	Investigative	NA	[28]
NRL-0301	DMC23G4	Investigative	NA	[28]
PN-2XXX	DMB3E38	Investigative	NA	[28]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 91 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ADAMTS13	TTUREBK	Limited	Biomarker	[29]
ADAMTS5	TTXSU2Y	Limited	Genetic Variation	[30]
ADRA2A	TTWG9A4	Limited	Biomarker	[31]
FABP4	TTHWMFZ	Limited	Biomarker	[32]
FFAR1	TTB8FUC	Limited	Biomarker	[33]
GCGR	TT9O6WS	Limited	Biomarker	[34]
GPBAR1	TTSDVTR	Limited	Biomarker	[35]
GPR119	TT7QNVC	Limited	Biomarker	[36]
LBP	TTVQJLY	Limited	Biomarker	[37]
LDLR	TTH0DUS	Limited	Biomarker	[38]
LIPA	TTS8T1M	Limited	Altered Expression	[39]
MGAM	TTXWASR	Limited	Altered Expression	[40]
MLYCD	TT9Z4YD	Limited	Biomarker	[41]
NPPC	TTRK0B9	Limited	Altered Expression	[42]
PPARGC1B	TTKSQ3W	Limited	Biomarker	[43]
SLC10A2	TTPI1M5	Limited	Biomarker	[44]
TMBIM6	TT7QSMG	Limited	Biomarker	[45]
ALDH2	TTFLN4T	Disputed	Biomarker	[46]
CAT	TTPS279	Disputed	Biomarker	[46]
PPARD	TT2JWF6	Disputed	Therapeutic	[47]
SIRT1	TTUF2HO	Disputed	Altered Expression	[48]
ACAT1	TTK3C21	moderate	Biomarker	[49]
ADRB3	TTMXGCW	moderate	Genetic Variation	[50]
BCAT1	TTES57P	moderate	Biomarker	[51]
GIP	TT40HS5	moderate	Biomarker	[52]
LEP	TTBJEZ5	moderate	Biomarker	[53]
MAP3K11	TTETX6Q	moderate	Biomarker	[54]
NPC1L1	TTPD1CN	moderate	Biomarker	[55]
PEMT	TT735V2	moderate	Genetic Variation	[56]
SLC11A2	TT2IS7P	moderate	Altered Expression	[57]
SLCO1A2	TTUGD21	moderate	Altered Expression	[58]
ABCB4	TTJUXV6	Strong	Biomarker	[59]
ABCC2	TTFLHJV	Strong	Biomarker	[60]
ADH1A	TT5AHZ0	Strong	Biomarker	[46]
ADIPOQ	TTXKA7D	Strong	Biomarker	[61]
AHCY	TTE2KUJ	Strong	Biomarker	[62]
AHR	TT037IE	Strong	Biomarker	[63]
CD14	TT6I7DC	Strong	Biomarker	[64]
CD36	TTPJMCU	Strong	Biomarker	[65]
CEACAM1	TTA9CK4	Strong	Genetic Variation	[66]
CFLAR	TTJZQYH	Strong	Biomarker	[67]
CHIT1	TTDYX6T	Strong	Altered Expression	[68]
CLCN2	TT30NW6	Strong	Altered Expression	[69]
CMKLR1	TT4UGZL	Strong	Biomarker	[70]
CPA1	TT3LJ6G	Strong	Biomarker	[71]
CSF2	TTNYZG2	Strong	Biomarker	[72]
CYP17A1	TTRA5BZ	Strong	Biomarker	[73]
CYP1A2	TTS1DTU	Strong	Biomarker	[74]
EIF2AK1	TTRUJBV	Strong	Biomarker	[47]
F2	TT6L509	Strong	Biomarker	[75]
FAS	TT7LTUJ	Strong	Biomarker	[76]
FGF19	TTGCH11	Strong	Biomarker	[77]
FGF21	TTQ916P	Strong	Biomarker	[78]
FGR	TTPOGS1	Strong	Biomarker	[79]
FOLR2	TTT54CI	Strong	Biomarker	[80]
GLP1R	TTVIMDE	Strong	Altered Expression	[81]
GSTA1	TT4P8DE	Strong	Biomarker	[82]
GSTP1	TT40K12	Strong	Biomarker	[83]
IL13RA2	TTMPZ7V	Strong	Biomarker	[84]
IL1A	TTPM6HI	Strong	Altered Expression	[72]
IL4	TTLGTKB	Strong	Biomarker	[72]
ITPR2	TTK9OV3	Strong	Altered Expression	[85]
JAK2	TTRMX3V	Strong	Biomarker	[86]
KLB	TTARBVH	Strong	Biomarker	[47]
LIF	TTGZ5WN	Strong	Biomarker	[72]
MADCAM1	TTBD6I7	Strong	Altered Expression	[87]
MAP3K5	TTOQCD8	Strong	Biomarker	[88]
MC4R	TTD0CIQ	Strong	Biomarker	[89]
MGAT2	TTJOW1I	Strong	Biomarker	[90]
MMP1	TTMX39J	Strong	Biomarker	[72]
MTTP	TTUS1RD	Strong	Biomarker	[91]
NFE2L2	TTA6ZN2	Strong	Biomarker	[92]
NQO1	TT8XK6L	Strong	Biomarker	[47]
NR1H4	TTS4UGC	Strong	Biomarker	[35]
NR5A2	TTAU3SY	Strong	Biomarker	[93]
PNPLA3	TTEUAEH	Strong	Genetic Variation	[94]
PPARA	TTJ584C	Strong	Altered Expression	[95]
PRDX4	TTPBL9I	Strong	Biomarker	[96]
PRKACA	TT5U49F	Strong	Biomarker	[60]
PRKCA	TTFJ8Q1	Strong	Biomarker	[60]
PRKCD	TT7A1BO	Strong	Biomarker	[60]
PRKCE	TT57MT2	Strong	Biomarker	[60]
RBP4	TT0C8BY	Strong	Altered Expression	[97]
SCARB1	TTRE324	Strong	Biomarker	[98]
SLC5A2	TTF8JAT	Strong	Biomarker	[99]
SREBF1	TTER0UB	Strong	Biomarker	[100]
STC2	TT4EFTR	Strong	Biomarker	[101]
TICAM1	TT2GQT6	Strong	Biomarker	[102]
TLR6	TTWRI8V	Strong	Altered Expression	[103]
TM6SF2	TTE1OHM	Strong	Genetic Variation	[104]
TNFRSF1B	TT63WSF	Strong	Biomarker	[64]
------------------------------------------------------------------------------------


⏷ Show the Full List of 91 DTT(s)

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC51A	DTMEQ32	Strong	Altered Expression	[105]
------------------------------------------------------------------------------------

This Disease Is Related to 11 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
GSTA4	DEH7XYP	Limited	Genetic Variation	[106]
SI	DE5EO4Y	Limited	Altered Expression	[40]
ADH1B	DEEN9RD	Disputed	Biomarker	[46]
ADH1C	DEM1HNL	moderate	Biomarker	[107]
MAT1A	DEQ6NC9	moderate	Biomarker	[49]
ADH4	DEOCWU3	Strong	Biomarker	[46]
ALDH1A1	DE2JP1Y	Strong	Biomarker	[46]
ALDH1B1	DEXI4UQ	Strong	Biomarker	[46]
GPT	DER5HFI	Strong	Biomarker	[108]
GSTM1	DEYZEJA	Strong	Biomarker	[107]
GSTT1	DE3PKUG	Strong	Biomarker	[107]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DME(s)

This Disease Is Related to 72 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
AEBP1	OTBI1RZ6	Limited	Biomarker	[109]
ARSH	OTG0X9UQ	Limited	Genetic Variation	[110]
AWAT1	OT8OTY3E	Limited	Biomarker	[111]
BHLHE23	OTLSVD17	Limited	Biomarker	[112]
ENHO	OT91QASK	Limited	Biomarker	[113]
FBL	OTRODIE5	Limited	Biomarker	[114]
FBXW5	OT5TQK3H	Limited	Biomarker	[115]
FNDC5	OT5CSK9X	Limited	Genetic Variation	[116]
GGTLC1	OTWJKUHQ	Limited	Altered Expression	[117]
GNMT	OT0O2OQO	Limited	Altered Expression	[118]
IBTK	OTB2GM4G	Limited	Biomarker	[119]
IL20RA	OTSIVBVS	Limited	Biomarker	[120]
JCAD	OT7G1WJW	Limited	Biomarker	[121]
LPCAT3	OTWI96P4	Limited	Biomarker	[122]
MOCOS	OT0TL3Q5	Limited	Genetic Variation	[41]
MYOM2	OTD2UOXW	Limited	Biomarker	[123]
NRF1	OTOXWNV8	Limited	Biomarker	[124]
RTL1	OTOT33IM	Limited	Biomarker	[125]
SETMAR	OTE2MIMZ	Limited	Biomarker	[125]
SMCP	OTXKY794	Limited	Genetic Variation	[41]
ST3GAL4	OTNENJZQ	Limited	Biomarker	[126]
STAM	OT6X5RR1	Limited	Biomarker	[127]
STK24	OTGUHOIL	Limited	Biomarker	[123]
SUV39H2	OTU0F4LL	Limited	Biomarker	[128]
PDK4	OTCMHMBZ	Disputed	Biomarker	[129]
ACO1	OT2VUR7L	moderate	Altered Expression	[57]
ELOVL6	OTB26UJJ	moderate	Biomarker	[130]
PSPH	OTV1PVAX	moderate	Biomarker	[51]
SHMT1	OTIINA3J	moderate	Biomarker	[51]
ACE	OTDF1964	Strong	Biomarker	[72]
ACSL4	OTI71MUJ	Strong	Genetic Variation	[131]
ALDH4A1	OT25Z6XH	Strong	Biomarker	[46]
ARNT	OTMSIEZY	Strong	Biomarker	[132]
ATP5F1B	OTLFZUQK	Strong	Biomarker	[133]
B3GAT1	OTXFP98E	Strong	Biomarker	[134]
CISD2	OTVS7S2H	Strong	Biomarker	[135]
CPT1A	OTI862QH	Strong	Biomarker	[47]
FOXA3	OTRGT2OT	Strong	Altered Expression	[136]
GABPA	OT9YB2SA	Strong	Biomarker	[92]
GPS2	OT065FSS	Strong	Biomarker	[95]
GSDMD	OTH39BKI	Strong	Biomarker	[137]
HCFC1	OT0UCK62	Strong	Biomarker	[138]
HFE	OTDD93KB	Strong	Biomarker	[139]
HSPA12A	OTFOCDD6	Strong	Biomarker	[140]
IKBKG	OTNWJWSD	Strong	Biomarker	[141]
IL3	OT0CQ35N	Strong	Biomarker	[72]
INTU	OTXB13E6	Strong	Biomarker	[35]
KRT18	OTVLQFIP	Strong	Biomarker	[142]
LAMA1	OTQZMP86	Strong	Biomarker	[72]
LGALS14	OTOR23GX	Strong	Altered Expression	[69]
LGALS3BP	OT9AGQKH	Strong	Altered Expression	[143]
LITAF	OTT5JX1F	Strong	Biomarker	[144]
LRPAP1	OT6DVD2Q	Strong	Biomarker	[145]
MT1B	OTUA4FFH	Strong	Genetic Variation	[146]
NCOA2	OTMQFPBB	Strong	Biomarker	[79]
NMU	OTW9X7BQ	Strong	Biomarker	[147]
OR10A4	OTYYB8SY	Strong	Genetic Variation	[148]
PLPP3	OTSSF7BK	Strong	Altered Expression	[149]
PNPLA2	OTR3ERMR	Strong	Biomarker	[150]
PRF1	OTFVXD7H	Strong	Biomarker	[134]
PRX	OT34Z10B	Strong	Biomarker	[151]
RAB5A	OTFR2KM4	Strong	Altered Expression	[149]
RAG2	OTG9UYTW	Strong	Biomarker	[134]
RDX	OTNSYUN6	Strong	Biomarker	[60]
SAMM50	OTRYFYIU	Strong	Genetic Variation	[152]
SART1	OTHMOGO1	Strong	Biomarker	[153]
SERPINB2	OT72QLZB	Strong	Biomarker	[72]
SLC25A47	OT5NGRWC	Strong	Altered Expression	[154]
SRSF3	OTOFT707	Strong	Genetic Variation	[155]
TRIB3	OTG5OS7X	Strong	Biomarker	[47]
TRIM69	OTTEGTRD	Strong	Biomarker	[102]
TRPC4AP	OTNJ9IFS	Strong	Altered Expression	[156]
------------------------------------------------------------------------------------


⏷ Show the Full List of 72 DOT(s)

References

1	Clinical pipeline report, company report or official report of Klus Pharma
2	ClinicalTrials.gov (NCT02704403) Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH) (RESOLVE-IT). U.S. National Institutes of Health.
3	ClinicalTrials.gov (NCT03449446) Study to Evaluate the Safety and Efficacy of Selonsertib, Firsocostat, Cilofexor, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (ATLAS). U.S. National Institutes of Health.
4	ClinicalTrials.gov (NCT04210245) Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4). U.S.National Institutes of Health.
5	ClinicalTrials.gov (NCT00668070) A Proof-of-principle Study of Oral Treatment of Non-alcoholic Steatohepatitis With a Novel PDE4 Inhibitor ASP9831 (ASTER). U.S. National Institutes of Health.
6	ClinicalTrials.gov (NCT04480710) A Study of CRV431 Dosed Once Daily in NASH Induced F2 and F3 Subjects (AMBITION). U.S. National Institutes of Health.
7	ClinicalTrials.gov (NCT04378010) A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH. U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT04944992) A Phase 2a, Randomized, Active-Comparator-Controlled, Open-Label Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Individuals With Nonalcoholic Fatty Liver Disease. U.S.National Institutes of Health.
9	ClinicalTrials.gov (NCT03812029) Safety, Tolerability, Pharmacokinetics and Efficacy of EYP001a in Patients With Nonalcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
10	ClinicalTrials.gov (NCT01899859) Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis. U.S. National Institutes of Health.
11	ClinicalTrials.gov (NCT05583344) 17 beta-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Nonalcoholic Steatohepatitis. U.S.National Institutes of Health.
12	ClinicalTrials.gov (NCT04874233) A 61-day Randomized, Double Blind, Placebo-controlled Trial to Assess the Safety and Efficacy of Three Doses of HU6 in Subjects With Elevated Liver Fat and High Body Mass Index (28 to 45 kg/m2). U.S.National Institutes of Health.
13	ClinicalTrials.gov (NCT05809934) A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants With Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) With Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele. U.S.National Institutes of Health.
14	ClinicalTrials.gov (NCT03008070) Phase 2b Study in NASH to Assess IVA337 (NATIVE). U.S. National Institutes of Health.
15	ClinicalTrials.gov (NCT02913105) Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH. U.S. National Institutes of Health.
16	ClinicalTrials.gov (NCT04702490) Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH. U.S. National Institutes of Health.
17	ClinicalTrials.gov (NCT04583423) A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis. U.S.National Institutes of Health.
18	ClinicalTrials.gov (NCT04321031) A PHASE 2, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, DOSE-RANGING, DOSE-FINDING, PARALLEL GROUP STUDY TO ASSESS EFFICACY AND SAFETY OF PF-06865571 (DGAT2I) ALONE AND WHEN COADMINISTERED WITH PF-05221304 (ACCI) IN ADULT PARTICIPANTS WITH BIOPSY-CONFIRMED NONALCOHOLIC STEATOHEPATITIS AND FIBROSIS STAGE 2 OR 3. U.S.National Institutes of Health.
19	Clinical pipeline report, company report or official report of AbbVie.
20	ClinicalTrials.gov (NCT04857606) A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 609 in Subjects With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
21	ClinicalTrials.gov (NCT05560607) An Open-label, Non-randomized, Multiple-dose Study to Assess the Knockdown of Hepatic HSD17B13 mRNA Expression, Pharmacokinetics, Safety, and Tolerability Following Administration of AZD7503 in Participants With Non-alcoholic Fatty Liver Disease. U.S.National Institutes of Health.
22	Constrained peptides' time to shine. Nat Rev Drug Discov. 2018 Jul 30;17(8):531-533.
23	Clinical pipeline report, company report or official report of vTv Therapeutics.
24	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
25	ClinicalTrials.gov (NCT04844450) A Double-Blind, Placebo-Controlled, Randomized, Multipart, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered JNJ-75220795. U.S.National Institutes of Health.
26	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030689)
27	2005 approvals: Safety first. Nature Reviews Drug Discovery 5, 92-93 (February 2006).
28	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
29	ADAMTS13 deficiency promotes microthrombosis in a murine model of diet-induced liver steatosis.Thromb Haemost. 2017 Jan 5;117(1):19-26. doi: 10.1160/TH16-03-0195. Epub 2016 Sep 8.
30	Functional role of ADAMTS5 in adiposity and metabolic health.PLoS One. 2018 Jan 2;13(1):e0190595. doi: 10.1371/journal.pone.0190595. eCollection 2018.
31	Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.yexmp.2018.07.005. Epub 2018 Jul 17.
32	Beneficial Effects of Korean Red Ginseng in the Progression of Non-Alcoholic Steatohepatitis via FABP4 Modulation.Am J Chin Med. 2018 Oct 9:1-27. doi: 10.1142/S0192415X18500817. Online ahead of print.
33	RLA8-A New and Highly Effective Quadruple PPAR-// and GPR40 Agonist to Reverse Nonalcoholic Steatohepatitis and Fibrosis.J Pharmacol Exp Ther. 2019 Apr;369(1):67-77. doi: 10.1124/jpet.118.255216. Epub 2019 Feb 11.
34	MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.Br J Clin Pharmacol. 2018 Oct;84(10):2325-2335. doi: 10.1111/bcp.13688. Epub 2018 Aug 7.
35	INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis.World J Gastroenterol. 2018 Jan 14;24(2):195-210. doi: 10.3748/wjg.v24.i2.195.
36	Co-administration of APD668, a G protein-coupled receptor 119 agonist and linagliptin, a DPPIV inhibitor, prevents progression of steatohepatitis in mice fed on a high trans-fat diet.Biochem Biophys Res Commun. 2018 Jan 8;495(2):1608-1613. doi: 10.1016/j.bbrc.2017.12.004. Epub 2017 Dec 5.
37	Association between endotoxemia and histological features of nonalcoholic fatty liver disease.World J Gastroenterol. 2017 Jan 28;23(4):712-722. doi: 10.3748/wjg.v23.i4.712.
38	Amitriptyline inhibits nonalcoholic steatohepatitis and atherosclerosis induced by high-fat diet and LPS through modulation of sphingolipid metabolism.Am J Physiol Endocrinol Metab. 2020 Feb 1;318(2):E131-E144. doi: 10.1152/ajpendo.00181.2019. Epub 2019 Dec 10.
39	Reduced lysosomal acid lipase activity: A new marker of liver disease severity across the clinical continuum of non-alcoholic fatty liver disease?.World J Gastroenterol. 2019 Aug 14;25(30):4172-4180. doi: 10.3748/wjg.v25.i30.4172.
40	The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH.Mar Drugs. 2017 Feb 15;15(2):41. doi: 10.3390/md15020041.
41	Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.Biochem Biophys Res Commun. 2018 Jan 22;495(4):2649-2656. doi: 10.1016/j.bbrc.2017.12.143. Epub 2017 Dec 24.
42	C-type natriuretic peptide (CNP) in endothelial cells attenuates hepatic fibrosis and inflammation in non-alcoholic steatohepatitis.Life Sci. 2018 Sep 15;209:349-356. doi: 10.1016/j.lfs.2018.08.031. Epub 2018 Aug 13.
43	Metabolic aspects in NAFLD, NASH and hepatocellular carcinoma: the role of PGC1 coactivators.Nat Rev Gastroenterol Hepatol. 2019 Mar;16(3):160-174. doi: 10.1038/s41575-018-0089-3.
44	Apical sodium-dependent bile acid transporter inhibition with volixibat improves metabolic aspects and components of non-alcoholic steatohepatitis in Ldlr-/-.Leiden mice.PLoS One. 2019 Jun 24;14(6):e0218459. doi: 10.1371/journal.pone.0218459. eCollection 2019.
45	Bax inhibitor-1 protects from nonalcoholic steatohepatitis by limiting inositol-requiring enzyme 1 alpha signaling in mice.Hepatology. 2018 Aug;68(2):515-532. doi: 10.1002/hep.29847. Epub 2018 May 18.
46	Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis.Toxicol Sci. 2018 Aug 1;164(2):428-438. doi: 10.1093/toxsci/kfy106.
47	Hepatic regulation of VLDL receptor by PPAR/ and FGF21 modulates non-alcoholic fatty liver disease.Mol Metab. 2018 Feb;8:117-131. doi: 10.1016/j.molmet.2017.12.008. Epub 2017 Dec 19.
48	Skeletal muscle miR-34a/SIRT1:AMPK axis is activated in experimental and human non-alcoholic steatohepatitis.J Mol Med (Berl). 2019 Aug;97(8):1113-1126. doi: 10.1007/s00109-019-01796-8. Epub 2019 May 28.
49	Methionine adenosyltransferases in liver cancer.World J Gastroenterol. 2019 Aug 21;25(31):4300-4319. doi: 10.3748/wjg.v25.i31.4300.
50	Polymorphisms of interleukin-1 beta and beta 3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis.Alcohol Clin Exp Res. 2004 Aug;28(s2):106S-110S. doi: 10.1111/j.1530-0277.2004.tb03226.x.
51	Genome-scale metabolic modelling of hepatocytes reveals serine deficiency in patients with non-alcoholic fatty liver disease.Nat Commun. 2014;5:3083. doi: 10.1038/ncomms4083.
52	Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver.Am J Clin Nutr. 2009 Feb;89(2):558-67. doi: 10.3945/ajcn.2008.26720. Epub 2009 Jan 13.
53	New evidence for the therapeutic potential of curcumin to treat nonalcoholic fatty liver disease in humans.PLoS One. 2017 Mar 3;12(3):e0172900. doi: 10.1371/journal.pone.0172900. eCollection 2017.
54	Mixed-lineage kinase 3 pharmacological inhibition attenuates murine nonalcoholic steatohepatitis.JCI Insight. 2017 Aug 3;2(15):e94488. doi: 10.1172/jci.insight.94488. eCollection 2017 Aug 3.
55	Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis.Free Radic Biol Med. 2016 Oct;99:520-532. doi: 10.1016/j.freeradbiomed.2016.09.009. Epub 2016 Sep 12.
56	Total liver phosphatidylcholine content associates with non-alcoholic steatohepatitis and glycine N-methyltransferase expression.Liver Int. 2019 Oct;39(10):1895-1905. doi: 10.1111/liv.14174. Epub 2019 Jul 8.
57	Increased duodenal iron absorption through up-regulation of divalent metal transporter 1 from enhancement of iron regulatory protein 1 activity in patients with nonalcoholic steatohepatitis.Hepatology. 2015 Sep;62(3):751-61. doi: 10.1002/hep.27774. Epub 2015 Apr 8.
58	Synergistic interaction between genetics and disease on pravastatin disposition.J Hepatol. 2014 Jul;61(1):139-47. doi: 10.1016/j.jhep.2014.02.021. Epub 2014 Mar 5.
59	Therapeutic effect of bezafibrate against biliary damage: a study of phospholipid secretion via the PPARalpha-MDR3 pathway.Int J Clin Pharmacol Ther. 2010 Jan;48(1):22-8. doi: 10.5414/cpp48022.
60	Misregulation of membrane trafficking processes in human nonalcoholic steatohepatitis.J Biochem Mol Toxicol. 2018 Mar;32(3):e22035. doi: 10.1002/jbt.22035. Epub 2018 Jan 17.
61	Angiotensin-(1-7) improves non-alcoholic steatohepatitis through an adiponectin-independent mechanism.Hepatol Res. 2017 Jan;47(1):116-122. doi: 10.1111/hepr.12707. Epub 2016 Apr 28.
62	Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma.FASEB J. 2018 Mar;32(3):1591-1601. doi: 10.1096/fj.201700866R. Epub 2018 Jan 3.
63	Functions of aryl hydrocarbon receptor (AHR) and CD38 in NAD metabolism and nonalcoholic steatohepatitis (NASH).Biochem Pharmacol. 2019 Nov;169:113620. doi: 10.1016/j.bcp.2019.08.022. Epub 2019 Aug 26.
64	Elevated endotoxin levels in non-alcoholic fatty liver disease.J Inflamm (Lond). 2010 Mar 30;7:15. doi: 10.1186/1476-9255-7-15.
65	CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.J Hepatol. 2018 Sep;69(3):705-717. doi: 10.1016/j.jhep.2018.04.006. Epub 2018 Apr 27.
66	CEACAM1 in Liver Injury, Metabolic and Immune Regulation.Int J Mol Sci. 2018 Oct 11;19(10):3110. doi: 10.3390/ijms19103110.
67	Silibinin ameliorates hepatic lipid accumulation and oxidative stress in mice with non-alcoholic steatohepatitis by regulating CFLAR-JNK pathway.Acta Pharm Sin B. 2019 Jul;9(4):745-757. doi: 10.1016/j.apsb.2019.02.006. Epub 2019 Feb 22.
68	Chitotriosidase gene expression in Kupffer cells from patients with non-alcoholic fatty liver disease.Gut. 2006 Sep;55(9):1313-20. doi: 10.1136/gut.2005.075697. Epub 2006 Jul 6.
69	Lack of ClC-2 Alleviates High Fat Diet-Induced Insulin Resistance and Non-Alcoholic Fatty Liver Disease.Cell Physiol Biochem. 2018;45(6):2187-2198. doi: 10.1159/000488164. Epub 2018 Mar 10.
70	Chemokine (CC-motif) receptor-like 2 mRNA is expressed in hepatic stellate cells and is positively associated with characteristics of non-alcoholic steatohepatitis in mice and men.Exp Mol Pathol. 2017 Aug;103(1):1-8. doi: 10.1016/j.yexmp.2017.06.001. Epub 2017 Jun 15.
71	Interobserver Variability in Histologic Evaluation of Liver Fibrosis Using Categorical and Quantitative Scores.Am J Clin Pathol. 2017 Apr 1;147(4):364-369. doi: 10.1093/ajcp/aqx011.
72	Liver transcriptional profile of atherosclerosis-related genes in human nonalcoholic fatty liver disease.Atherosclerosis. 2011 Oct;218(2):378-85. doi: 10.1016/j.atherosclerosis.2011.05.014. Epub 2011 May 18.
73	CYP17 polymorphism as a risk factor of tamoxifen-induced hepatic steatosis in breast cancer patients.Oncol Rep. 2005 Mar;13(3):485-9.
74	The impact of serotonergic system dysfunction on the regulation of P4501A isoforms during liver insufficiency and consequences for thyroid hormone homeostasis.Food Chem Toxicol. 2016 Nov;97:70-81. doi: 10.1016/j.fct.2016.08.027. Epub 2016 Aug 24.
75	Therapeutic administration of the direct thrombin inhibitor argatroban reduces hepatic inflammation in mice with established fatty liver disease.Am J Pathol. 2012 Oct;181(4):1287-95. doi: 10.1016/j.ajpath.2012.06.011. Epub 2012 Jul 26.
76	Evaluation of the therapeutic potential effect of Fas receptor gene knockdown in experimental model of non-alcoholic steatohepatitis.Free Radic Res. 2019 May;53(5):486-496. doi: 10.1080/10715762.2019.1608982. Epub 2019 May 7.
77	NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis.Hepatology. 2020 Apr;71(4):1198-1212. doi: 10.1002/hep.30590. Epub 2019 Apr 10.
78	Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.J Clin Endocrinol Metab. 2019 Aug 1;104(8):3327-3336. doi: 10.1210/jc.2018-02414.
79	Genetic and Environmental Models of Circadian Disruption Link SRC-2 Function to Hepatic Pathology.J Biol Rhythms. 2016 Oct;31(5):443-60. doi: 10.1177/0748730416657921. Epub 2016 Jul 17.
80	Folate receptor-beta expression as a diagnostic target in human & rodent nonalcoholic steatohepatitis.Toxicol Appl Pharmacol. 2019 Apr 1;368:49-54. doi: 10.1016/j.taap.2019.02.009. Epub 2019 Feb 19.
81	Sodium butyrate reduces high-fat diet-induced non-alcoholic steatohepatitis through upregulation of hepatic GLP-1R expression.Exp Mol Med. 2018 Dec 3;50(12):1-12. doi: 10.1038/s12276-018-0183-1.
82	Interactive effects of smoking and glutathione S-transferase polymorphisms on the development of non-alcoholic fatty liver disease.Toxicol Lett. 2013 Jul 4;220(2):143-9. doi: 10.1016/j.toxlet.2013.04.019. Epub 2013 Apr 30.
83	The different expression of tumor suppressors, RASSF1A, RUNX3, and GSTP1, in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH).Exp Mol Pathol. 2019 Jun;108:156-163. doi: 10.1016/j.yexmp.2019.04.002. Epub 2019 Apr 3.
84	Novel role of IL-13 in fibrosis induced by nonalcoholic steatohepatitis and its amelioration by IL-13R-directed cytotoxin in a rat model.J Immunol. 2008 Oct 1;181(7):4656-65. doi: 10.4049/jimmunol.181.7.4656.
85	Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor.Hepatology. 2018 Feb;67(2):560-574. doi: 10.1002/hep.29588. Epub 2018 Jan 2.
86	Janus Kinase 2 (JAK2) Dissociates Hepatosteatosis from Hepatocellular Carcinoma in Mice.J Biol Chem. 2017 Mar 3;292(9):3789-3799. doi: 10.1074/jbc.M116.752519. Epub 2017 Jan 18.
87	(7)-Integrin and MAdCAM-1 play opposing roles during the development of non-alcoholic steatohepatitis.J Hepatol. 2017 Jun;66(6):1251-1264. doi: 10.1016/j.jhep.2017.02.001. Epub 2017 Feb 10.
88	Hepatocyte TNF Receptor-Associated Factor 6 Aggravates Hepatic Inflammation and Fibrosis by Promoting Lysine 6-Linked Polyubiquitination of Apoptosis Signal-Regulating Kinase 1.Hepatology. 2020 Jan;71(1):93-111. doi: 10.1002/hep.30822. Epub 2019 Aug 20.
89	Evaluation of hepatic function using dynamic contrast-enhanced magnetic resonance imaging in melanocortin 4 receptor-deficient mice as a model of nonalcoholic steatohepatitis.Magn Reson Imaging. 2019 Apr;57:210-217. doi: 10.1016/j.mri.2018.11.013. Epub 2018 Nov 19.
90	Monoacylglycerol Acyltransferase 2 (MGAT2) Inhibitors for the Treatment of Metabolic Diseases and Nonalcoholic Steatohepatitis (NASH).J Med Chem. 2018 Nov 21;61(22):9879-9888. doi: 10.1021/acs.jmedchem.8b00864. Epub 2018 Jul 17.
91	Novel findings for the development of drug therapy for various liver diseases: Liver microsomal triglyceride transfer protein activator may be a possible therapeutic agent in non-alcoholic steatohepatitis.J Pharmacol Sci. 2011;115(3):270-3. doi: 10.1254/jphs.10r14fm. Epub 2011 Feb 22.
92	Carbon monoxide releasing molecule-A1 improves nonalcoholic steatohepatitis via Nrf2 activation mediated improvement in oxidative stress and mitochondrial function.Redox Biol. 2020 Jan;28:101314. doi: 10.1016/j.redox.2019.101314. Epub 2019 Aug 31.
93	LRH-1 regulates hepatic lipid homeostasis and maintains arachidonoyl phospholipid pools critical for phospholipid diversity.JCI Insight. 2018 Mar 8;3(5):e96151. doi: 10.1172/jci.insight.96151.
94	Validation of PNPLA3 polymorphisms as risk factor for NAFLD and liver fibrosis in an admixed population.Ann Hepatol. 2019 May-Jun;18(3):466-471. doi: 10.1016/j.aohep.2018.10.004. Epub 2019 Apr 18.
95	Hepatocyte-specific loss of GPS2 in mice reduces non-alcoholic steatohepatitis via activation of PPAR.Nat Commun. 2019 Apr 11;10(1):1684. doi: 10.1038/s41467-019-09524-z.
96	The Association of Peroxiredoxin 4 with the Initiation and Progression of Hepatocellular Carcinoma.Antioxid Redox Signal. 2019 Apr 1;30(10):1271-1284. doi: 10.1089/ars.2017.7426. Epub 2018 Jun 11.
97	Circulating retinol binding protein 4 levels in nonalcoholic fatty liver disease: a systematic review and meta-analysis.Lipids Health Dis. 2017 Sep 20;16(1):180. doi: 10.1186/s12944-017-0566-7.
98	Alleviative effects of resveratrol on nonalcoholic fatty liver disease are associated with up regulation of hepatic low density lipoprotein receptor and scavenger receptor class B type I gene expressions in rats.Food Chem Toxicol. 2013 Feb;52:12-8. doi: 10.1016/j.fct.2012.10.026. Epub 2012 Nov 2.
99	Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus.Dig Dis Sci. 2020 Feb;65(2):623-631. doi: 10.1007/s10620-019-5477-1. Epub 2019 Jan 25.
100	Protective effect of resveratrol derivatives on high-fat diet induced fatty liver by activating AMP-activated protein kinase.Arch Pharm Res. 2014;37(9):1169-76. doi: 10.1007/s12272-014-0347-z. Epub 2014 Mar 18.
101	The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease.Toxicol Sci. 2014 Jan;137(1):26-35. doi: 10.1093/toxsci/kft230. Epub 2013 Oct 4.
102	TLR3/4 signaling is mediated via the NFB-CXCR4/7 pathway in human alcoholic hepatitis and non-alcoholic steatohepatitis which formed Mallory-Denk bodies.Exp Mol Pathol. 2014 Oct;97(2):234-40. doi: 10.1016/j.yexmp.2014.07.001. Epub 2014 Jul 2.
103	Increased Expression Profile and Functionality of TLR6 in Peripheral Blood Mononuclear Cells and Hepatocytes of Morbidly Obese Patients with Non-Alcoholic Fatty Liver Disease.Int J Mol Sci. 2016 Nov 10;17(11):1878. doi: 10.3390/ijms17111878.
104	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease.Hepatology. 2015 Feb;61(2):506-14. doi: 10.1002/hep.27490.
105	Organic solute transporter OST/ is overexpressed in nonalcoholic steatohepatitis and modulated by drugs associated with liver injury. Am J Physiol Gastrointest Liver Physiol. 2018 May 1;314(5):G597-G609.
106	Global Deletion of Glutathione S-Transferase A4 Exacerbates Developmental Nonalcoholic Steatohepatitis.Am J Pathol. 2017 Feb;187(2):418-430. doi: 10.1016/j.ajpath.2016.10.022. Epub 2016 Dec 18.
107	Genetic Association and Gene-Gene Interaction Reveal Genetic Variations in ADH1B, GSTM1 and MnSOD Independently Confer Risk to Alcoholic Liver Diseases in India.PLoS One. 2016 Mar 3;11(3):e0149843. doi: 10.1371/journal.pone.0149843. eCollection 2016.
108	Predictors of nonalcoholic steatohepatitis and significant fibrosis in non-obese nonalcoholic fatty liver disease.Liver Int. 2019 Feb;39(2):332-341. doi: 10.1111/liv.13983. Epub 2018 Oct 27.
109	Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis.J Clin Invest. 2018 Apr 2;128(4):1581-1596. doi: 10.1172/JCI92863. Epub 2018 Mar 19.
110	Digoxin Suppresses Pyruvate Kinase M2-Promoted HIF-1 Transactivation in Steatohepatitis.Cell Metab. 2018 Feb 6;27(2):339-350.e3. doi: 10.1016/j.cmet.2018.01.007.
111	Targeting diacylglycerol acyltransferase 2 for the treatment of nonalcoholic steatohepatitis.Sci Transl Med. 2019 Nov 27;11(520):eaav9701. doi: 10.1126/scitranslmed.aav9701.
112	Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis.Rev Esp Enferm Dig. 2018 Jan;110(1):19-24. doi: 10.17235/reed.2017.4690/2016.
113	Adropin protects against liver injury in nonalcoholic steatohepatitis via the Nrf2 mediated antioxidant capacity.Redox Biol. 2019 Feb;21:101068. doi: 10.1016/j.redox.2018.101068. Epub 2018 Dec 6.
114	Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.Dig Dis. 2017;35(6):521-530. doi: 10.1159/000480142. Epub 2017 Oct 17.
115	F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice.Hepatology. 2019 Dec;70(6):1942-1957. doi: 10.1002/hep.30537. Epub 2019 Mar 15.
116	Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.J Clin Endocrinol Metab. 2017 Aug 1;102(8):2660-2669. doi: 10.1210/jc.2017-00056.
117	Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme.Diabet Med. 2018 Oct;35(10):1434-1439. doi: 10.1111/dme.13697. Epub 2018 Jun 22.
118	miR-873-5p targets mitochondrial GNMT-Complex II interface contributing to non-alcoholic fatty liver disease.Mol Metab. 2019 Nov;29:40-54. doi: 10.1016/j.molmet.2019.08.008. Epub 2019 Aug 16.
119	Function of inhibitor of Bruton's tyrosine kinase isoform (IBTK) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.J Biol Chem. 2017 Aug 25;292(34):14050-14065. doi: 10.1074/jbc.M117.799304. Epub 2017 Jul 14.
120	The Interleukin-20 Cytokine Family in Liver Disease.Front Immunol. 2018 May 28;9:1155. doi: 10.3389/fimmu.2018.01155. eCollection 2018.
121	JCAD Promotes Progression of Nonalcoholic Steatohepatitis to Liver Cancer by Inhibiting LATS2 Kinase Activity.Cancer Res. 2017 Oct 1;77(19):5287-5300. doi: 10.1158/0008-5472.CAN-17-0229. Epub 2017 Aug 3.
122	Caspase-independent hepatocyte death: A result of the decrease of lysophosphatidylcholine acyltransferase 3 in non-alcoholic steatohepatitis.J Gastroenterol Hepatol. 2019 Jul;34(7):1256-1262. doi: 10.1111/jgh.14461. Epub 2018 Sep 23.
123	Protein kinase MST3 modulates lipid homeostasis in hepatocytes and correlates with nonalcoholic steatohepatitis in humans.FASEB J. 2019 Sep;33(9):9974-9989. doi: 10.1096/fj.201900356RR. Epub 2019 Jun 7.
124	Oncogenic Activation of Nrf2, Though as a Master Antioxidant Transcription Factor, Liberated by Specific Knockout of the Full-Length Nrf1 that Acts as a Dominant Tumor Repressor.Cancers (Basel). 2018 Dec 17;10(12):520. doi: 10.3390/cancers10120520.
125	Resolving inflammation in nonalcoholic steatohepatitis.J Clin Invest. 2019 Mar 11;129(4):1524-1526. doi: 10.1172/JCI127583. eCollection 2019 Mar 11.
126	Sex-dependent effects on gut microbiota regulate hepatic carcinogenic outcomes.Sci Rep. 2017 Mar 27;7:45232. doi: 10.1038/srep45232.
127	Connectivity mapping of angiotensin-PPAR interactions involved in the amelioration of non-alcoholic steatohepatitis by Telmisartan.Sci Rep. 2019 Mar 8;9(1):4003. doi: 10.1038/s41598-019-40322-1.
128	The histone methyltransferase Suv39h2 contributes to nonalcoholic steatohepatitis in mice.Hepatology. 2017 Jun;65(6):1904-1919. doi: 10.1002/hep.29127. Epub 2017 Apr 28.
129	Pyruvate dehydrogenase kinase 4 mediates lipogenesis and contributes to the pathogenesis of nonalcoholic steatohepatitis.Biochem Biophys Res Commun. 2018 Jan 1;495(1):582-586. doi: 10.1016/j.bbrc.2017.11.054. Epub 2017 Nov 9.
130	Elovl6 promotes nonalcoholic steatohepatitis.Hepatology. 2012 Dec;56(6):2199-208. doi: 10.1002/hep.25932.
131	Genome-wide analysis of DNA methylation in human peripheral leukocytes identifies potential biomarkers of nonalcoholic fatty liver disease.Int J Mol Med. 2018 Jul;42(1):443-452. doi: 10.3892/ijmm.2018.3583. Epub 2018 Mar 22.
132	Myeloid cell deletion of Aryl hydrocarbon Receptor Nuclear Translocator (ARNT) induces non-alcoholic steatohepatitis.PLoS One. 2019 Dec 4;14(12):e0225332. doi: 10.1371/journal.pone.0225332. eCollection 2019.
133	Urinary ATP Synthase Subunit Is a Novel Biomarker of Renal Mitochondrial Dysfunction in Acute Kidney Injury.Toxicol Sci. 2015 May;145(1):108-17. doi: 10.1093/toxsci/kfv038. Epub 2015 Feb 9.
134	CYP2E1-dependent and leptin-mediated hepatic CD57 expression on CD8+ T cells aid progression of environment-linked nonalcoholic steatohepatitis.Toxicol Appl Pharmacol. 2014 Jan 1;274(1):42-54. doi: 10.1016/j.taap.2013.10.029. Epub 2013 Nov 7.
135	CISD2 Haploinsufficiency Disrupts Calcium Homeostasis, Causes Nonalcoholic Fatty Liver Disease, and Promotes Hepatocellular Carcinoma.Cell Rep. 2017 Nov 21;21(8):2198-2211. doi: 10.1016/j.celrep.2017.10.099.
136	Hepatic Forkhead Box Protein A3 Regulates ApoA-I (Apolipoprotein A-I) Expression, Cholesterol Efflux, and Atherogenesis.Arterioscler Thromb Vasc Biol. 2019 Aug;39(8):1574-1587. doi: 10.1161/ATVBAHA.119.312610. Epub 2019 Jul 11.
137	Gasdermin D plays a key role as a pyroptosis executor of non-alcoholic steatohepatitis in humans and mice.J Hepatol. 2018 Apr;68(4):773-782. doi: 10.1016/j.jhep.2017.11.040. Epub 2017 Dec 20.
138	Rapid Recapitulation of Nonalcoholic Steatohepatitis upon Loss of Host Cell Factor 1 Function in Mouse Hepatocytes.Mol Cell Biol. 2019 Feb 15;39(5):e00405-18. doi: 10.1128/MCB.00405-18.
139	Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation.Dig Dis Sci. 2010 Mar;55(3):808-14. doi: 10.1007/s10620-009-0771-y. Epub 2009 Mar 7.
140	HSPA12A Is a Novel Player in Nonalcoholic Steatohepatitis via Promoting Nuclear PKM2-Mediated M1 Macrophage Polarization.Diabetes. 2019 Feb;68(2):361-376. doi: 10.2337/db18-0035. Epub 2018 Nov 19.
141	Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis.Gut. 2011 Mar;60(3):387-96. doi: 10.1136/gut.2010.223834. Epub 2010 Nov 29.
142	Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.J Gastroenterol Hepatol. 2020 Jun;35(6):1057-1064. doi: 10.1111/jgh.14894. Epub 2019 Dec 9.
143	Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.PLoS One. 2018 Aug 30;13(8):e0202226. doi: 10.1371/journal.pone.0202226. eCollection 2018.
144	LPS-induced TNF- factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.Oncotarget. 2015 Dec 8;6(39):41434-52. doi: 10.18632/oncotarget.5163.
145	Rapeseed Protein-Derived Antioxidant Peptide RAP Ameliorates Nonalcoholic Steatohepatitis and Related Metabolic Disorders in Mice.Mol Pharm. 2019 Jan 7;16(1):371-381. doi: 10.1021/acs.molpharmaceut.8b01030. Epub 2018 Dec 21.
146	Association of polymorphisms of glutamate-cystein ligase and microsomal triglyceride transfer protein genes in non-alcoholic fatty liver disease.J Gastroenterol Hepatol. 2010 Feb;25(2):357-61. doi: 10.1111/j.1440-1746.2009.06001.x. Epub 2009 Oct 9.
147	Role of neuromedin U in accelerating of non-alcoholic steatohepatitis in mice.Peptides. 2018 Jan;99:134-141. doi: 10.1016/j.peptides.2017.09.011. Epub 2017 Oct 7.
148	Haptoglobin 2-2 Genotype is Associated with More Advanced Disease in Subjects with Non-Alcoholic Steatohepatitis: A Retrospective Study.Adv Ther. 2019 Apr;36(4):880-895. doi: 10.1007/s12325-019-00902-z. Epub 2019 Feb 28.
149	Genomics of human fatty liver disease reveal mechanistically linked lipid droplet-associated gene regulations in bland steatosis and nonalcoholic steatohepatitis.Transl Res. 2016 Nov;177:41-69. doi: 10.1016/j.trsl.2016.06.003. Epub 2016 Jun 16.
150	iPla2 deficiency in mice fed with MCD diet does not correct the defect of phospholipid remodeling but attenuates hepatocellular injury via an inhibition of lipid uptake genes.Biochim Biophys Acta Mol Cell Biol Lipids. 2019 May;1864(5):677-687. doi: 10.1016/j.bbalip.2019.02.003. Epub 2019 Feb 5.
151	An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy.J Immunol Methods. 2017 Jul;446:21-29. doi: 10.1016/j.jim.2017.03.023. Epub 2017 Apr 7.
152	Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers.PLoS One. 2018 Jan 31;13(1):e0185490. doi: 10.1371/journal.pone.0185490. eCollection 2018.
153	A new HIF-1/RANTES-driven pathway to hepatocellular carcinoma mediated by germline haploinsufficiency of SART1/HAF in mice.Hepatology. 2016 May;63(5):1576-91. doi: 10.1002/hep.28468. Epub 2016 Mar 7.
154	Effect of miR-146 targeted HDMCP up-regulation in the pathogenesis of nonalcoholic steatohepatitis.PLoS One. 2017 Mar 27;12(3):e0174218. doi: 10.1371/journal.pone.0174218. eCollection 2017.
155	Degradation of splicing factor SRSF3 contributes to progressive liver disease.J Clin Invest. 2019 Aug 8;129(10):4477-4491. doi: 10.1172/JCI127374.
156	TRUSS Exacerbates NAFLD Development by Promoting IB Degradation in Mice.Hepatology. 2018 Nov;68(5):1769-1785. doi: 10.1002/hep.30066. Epub 2018 Oct 4.